To Whom It May Concern:

Company Name Taisho Pharmaceutical Holdings Co., Ltd.

Head Office 3-24-1 Takada, Toshima-ku, Tokyo Representative Akira Uehara, President and CEO

(First Section of TSE: Code 4581)

Contact Hideki Iuchi, General Manager Corporate

Communications Tel: +81-3-3985-1111

Notice Regarding the Result of the Tender Offer for Shares of Duoc Hau Giang Pharmaceutical JSC

Taisho Pharmaceutical Co., Ltd. [Headquarters: Toshima-ku, Tokyo, CEO: Shigeru Uehara] (hereinafter "Taisho"), a consolidated subsidiary of Taisho Pharmaceutical Holdings Co., Ltd., (hereinafter "Taisho Holdings") performed a Tender Offer - beginning on March 18, 2019 - targeting 21.7% of the total number of issued shares (hereinafter "Tender Offer") of Duoc Hau Giang Pharmaceutical JSC (hereinafter "DHG"), an equity method affiliate of Taisho Holdings based in Vietnam, aiming for consolidation of DHG as a consolidated subsidiary. The Tender Offer ended on April 16, 2019, and the result was as follows:

20,635,966 shares (15.78% of total number of issued shares) were tendered and the Tender Offer was therefore executed according to plan.

Moreover, the Tender Offer does not fall under the tender offer as prescribed in Article 27-2, Paragraph 1 of Japan's Financial Instruments and Exchange Act.

1. Outline of the Tender Offer (Announcement: February 28, 2019)

| (1) | Tender Offeror | Taisho Pharmaceutical Co., Ltd. | | |
|-----|------------------------------|--|--|--|
| (2) | Target | Duoc Hau Giang Pharmaceutical JSC | | |
| (3) | Tender Offer Period | From March 18, 2019 to April 16, 2019 (hereinafter "Tender Offer | | |
| | | Period") | | |
| | | Note: At the time of the announcement of the tender offer on | | |
| | | February 28, 2019, it was planned that the tender offer period would | | |
| | | begin in mid-March 2019 and end in mid-April 2019. After the | | |
| | | Vietnamese authorities approved the tender offer, the Tender Offer | | |
| | | Period has been fixed. | | |
| (4) | Class of Share Certificates, | Common shares | | |
| | Etc. to be Purchased | | | |
| (5) | Number of Shares to be | Number of shares to be purchased: 28,358,748 shares (21.7% of total | | |
| | Purchased | number of issued shares) | | |

2. Result of the Tender Offer

| (1) | Number of Shares | 20,635,966 shares (15.78% of total number of issued shares) | |
|-----|--------------------------|---|--|
| | Transferred | | |
| | | | |
| (2) | Purchase Price | 120,000 VND per share | |
| | | | |
| (3) | Share Transfer Execution | April 26, 2019 (planned) | |
| | Date | | |
| | Date | | |
| | | | |

3. Outline of the Tender Offer Target (DHG)

| (1) | Name | Duoc Hau Giang Pharmaceutical JSC | | | | |
|-----|--|---|--|---|-----------------------|--|
| (2) | Address | 288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Can Tho City, Vietnam | | | | |
| (3) | Name and Title of | Acting Chief Executive Officer: Duy Khuong Dinh Doan | | | | |
| | Representative | | | | | |
| (4) | Business Outline | Manufacture and sale of pharmaceuticals, sale of functional food etc. | | | | |
| (5) | Capital Stock | 1,307,460,710,000 VND | | | | |
| (6) | Establishment | 1974 | | | | |
| (7) | Sharahalding Dation | The State Capital Investment Corporation 43.31% | | | | |
| | | Taisho Pharmaceutical Co., Ltd. 34.99% | | | | |
| (8) | Relationship between Taisho and DHG | Capital | holds 45 of issued | consolidated subsidiary,761,086 shares (34.99% shares) of DHG as of the | % of the total number | |
| | | Personnel | Jun Kuroda, Member of the Board, Senior Executive Officer of Taisho, is concurrently serving as a director of DHG. | | | |
| (0) | | Business | Not appl | | | |
| (9) | Operating performance and financial condition (consolidated) in the last three fiscal years (Unit million JPY) * | | | | | |
| | Fiscal Years | FY2016 | | FY2017 | FY2018 | |
| | 1 100011 100110 | (ending Dec., 2016) | | (ending Dec., 2017) | (ending Dec., 2018) | |
| | Net Assets (Equity) | 13,488 | | 12,968 | 14,780 | |
| | Total Assets | 18,543 | | 19,211 | 19,773 | |
| | Sales | | 17,780 | 19,095 | 18,273 | |
| | Operating Income | | 3,685 | 3,443 | 3,321 | |
| | | | | | | |

^{*} Converted at the exchange rate: 1 VND = 0.0047 JPY

Net income

3,223

3,019

3,072

4. Number of Shares held by Taisho Before and After the Transfer / Purchase Price

| (1) | Number of Shares held | 45,761,086 shares (34.99% of total number of issued shares) |
|-----|----------------------------|---|
| | before the Transfer | |
| (2) | Number of Shares | 20,635,966 shares (15.78% of total number of issued shares) |
| | Transferred | |
| (3) | Purchase Price | 2,476.3 billion VND (approximately 11.7 billion JPY) * |
| (4) | Number of Shares after the | 66,397,052 shares (50.78% of total number of issued shares) |
| | Transfer | |

^{*} Converted at the exchange rate: 1 VND = 0.0047 JPY

5. Schedule

Share Transfer Execution Date: April 26, 2019 (planned)

6. Future Outlook

The timing of becoming a consolidated subsidiary and the impact of the transaction on the financial condition of Taisho Group will be announced as it is finalized.

End